Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

mehr ...

erschienen in

mehr ...

Verlag

mehr ...

Geographic terms

Sprache

Datenbank

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 43, Suchdauer: 0.88s

12 weiter »

1
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

von Kristeleit, R ; Leary, A ; Oaknin, A ; et al.
- View full text via BASE
Merkliste

2
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study

von Geoerger, B ; Zwaan, C.M. ; Marshall, LV ; et al.

Geoerger, B, Zwaan, C M, Marshall, LV, Michon, J, Bourdeaut, F, Casanova, M, Corradini, N, Rossato, G, Farid-Kapadia, M, Shemesh, CS, Hutchinson, KE, Donaldson, F, Liao, ML, Caron, H & Trippett, T 2020, 'Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study', Lancet Oncology, vol. 21, no. 1, pp. 134-144. https://doi.org/10.1016/s1470-2045(19)30693-x

Schlagworte: /dk/atira/pure/keywords/researchprograms/AFL001000/EMCMM025403; name=EMC MM-02-54-03
- Zum Volltext (via ReDI)
Merkliste

3
Higher education students' perceptions of ChatGPT: A global study of early reactions.

von Ravšelj D ; Keržič D ; Tomaževič N ; et al.

PloS one [PLoS One] 2025 Feb 05; Vol. 20 (2), pp. e0315011. Date of Electronic Publication: 2025 Feb 05 (Print Publication: 2025).
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

4
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.

von Finn RS ; Ryoo BY ; Hsu CH ; et al.

The Lancet. Oncology [Lancet Oncol] 2025 Feb; Vol. 26 (2), pp. 214-226. Date of Electronic Publication: 2025 Jan 21.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

5
Sensory Dysfunction, Microbial Infections, and Host Responses in Alzheimer's Disease.

von Bathini P ; Brai E ; Balin BJ ; et al.

The Journal of infectious diseases [J Infect Dis] 2024 Sep 10; Vol. 230 (Supplement_2), pp. S150-S164.
- Volltextverfügbarkeit prüfen (via ReDI)
- Zur Referenz in PubMed
Merkliste

6
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.

von Kristeleit R ; Leary A ; Oaknin A ; et al.

British journal of cancer [Br J Cancer] 2024 Sep; Vol. 131 (5), pp. 820-831. Date of Electronic Publication: 2024 Jul 06.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

7
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors.

von Shemesh CS ; Wang Y ; An A ; et al.

Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2024 Jul; Vol. 94 (1), pp. 45-55. Date of Electronic Publication: 2024 Mar 07.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

8
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).

von Garralda E ; Oh DY ; Italiano A ; et al.

Journal of clinical pharmacology [J Clin Pharmacol] 2024 May; Vol. 64 (5), pp. 544-554. Date of Electronic Publication: 2024 Jan 17.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

9
Applying Natural Language Processing to ClinicalTrials.gov: mRNA cancer vaccine case study.

von Vora B ; Kuruvilla D ; Kim C ; et al.

Clinical and translational science [Clin Transl Sci] 2023 Dec; Vol. 16 (12), pp. 2417-2420. Date of Electronic Publication: 2023 Oct 12.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

10
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).

von Drakaki A ; Powles T ; Bamias A ; et al.

Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Nov 01; Vol. 29 (21), pp. 4373-4384.
- Volltextverfügbarkeit prüfen (via ReDI)
- Zur Referenz in PubMed
Merkliste

11
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework.

von Shemesh CS ; Chan P ; Marchand M ; et al.

Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2023 Sep; Vol. 114 (3), pp. 644-651. Date of Electronic Publication: 2023 Jun 02.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

12
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.

von Ko AH ; Kim KP ; Siveke JT ; et al.

The oncologist [Oncologist] 2023 Jun 02; Vol. 28 (6), pp. 553-e472.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

13
Preoperative Pain Catastrophizing and Neuropathic Pain Do Not Predict Length of Stay and Early Post-Operative Complications following Total Joint Arthroplasty.

von Shemesh SS ; Dieterich JD ; Chen D ; et al.

Journal of personalized medicine [J Pers Med] 2023 Jan 26; Vol. 13 (2). Date of Electronic Publication: 2023 Jan 26.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

14
NKG2D receptor activation drives primary graft dysfunction severity and poor lung transplantation outcomes.

von Calabrese DR ; Tsao T ; Magnen M ; et al.

JCI insight [JCI Insight] 2022 Dec 22; Vol. 7 (24). Date of Electronic Publication: 2022 Dec 22.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

15
Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors.

von Huang W ; Stader F ; Chan P ; et al.

Frontiers in pharmacology [Front Pharmacol] 2022 Sep 26; Vol. 13, pp. 974423. Date of Electronic Publication: 2022 Sep 26 (Print Publication: 2022).
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

16
Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations.

von Lemaire V ; Shemesh CS ; Rotte A

Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2021 Oct 01; Vol. 40 (1), pp. 311. Date of Electronic Publication: 2021 Oct 01.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

17
Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.

von Shemesh CS ; Chan P ; Shao H ; et al.

Liver cancer [Liver Cancer] 2021 Jun 10; Vol. 10 (5), pp. 485-499. Date of Electronic Publication: 2021 Jun 10 (Print Publication: 2021).
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

18
Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions.

von Butler D ; Mozsary C ; Meydan C ; et al.

Nature communications [Nat Commun] 2021 Mar 12; Vol. 12 (1), pp. 1660. Date of Electronic Publication: 2021 Mar 12.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

19
The Utility of a Pre-Transplant Psychosocial Evaluation in Predicting Post-Liver Transplant Outcomes.

von Becker JH ; Shemesh E ; Shenoy A ; et al.

Progress in transplantation (Aliso Viejo, Calif.) [Prog Transplant] 2021 Mar; Vol. 31 (1), pp. 4-12. Date of Electronic Publication: 2020 Dec 04.
- Volltextverfügbarkeit prüfen (via ReDI)
- Zur Referenz in PubMed
Merkliste

20
Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.

von Shemesh CS ; Hsu JC ; Hosseini I ; et al.

Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2021 Feb 03; Vol. 29 (2), pp. 555-570. Date of Electronic Publication: 2020 Sep 30.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

21
Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden.

von Shemesh CS ; Chan P ; Legrand FA ; et al.

Pharmacology research & perspectives [Pharmacol Res Perspect] 2020 Dec; Vol. 8 (6), pp. e00685.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

22
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.

von Lu D ; Lu T ; Shi R ; et al.

Pharmaceutical research [Pharm Res] 2020 Dec 01; Vol. 37 (12), pp. 252. Date of Electronic Publication: 2020 Dec 01.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

23
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.

von Shemesh CS ; Agarwal P ; Lu T ; et al.

Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 May; Vol. 85 (5), pp. 831-842. Date of Electronic Publication: 2020 Mar 28.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

24
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.

von Lu D ; Lu T ; Gibiansky L ; et al.

CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2020 Jan; Vol. 9 (1), pp. 48-59. Date of Electronic Publication: 2019 Dec 23.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

25
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.

von Shemesh CS ; Chanu P ; Jamsen K ; et al.

Journal for immunotherapy of cancer [J Immunother Cancer] 2019 Nov 21; Vol. 7 (1), pp. 314. Date of Electronic Publication: 2019 Nov 21.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

12 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag